# Live Double Combined Lactobacillus Capsule for Vaginal Use（IIa）

> **NCT07418996** · PHASE2 · COMPLETED · sponsor: **Guangdong Longchuangji Pharmaceutical Co., Ltd.** · enrollment: 57 (actual)

## Conditions studied

- Bacterial Vaginosis (BV)

## Interventions

- **DRUG:** Live double combined lactobacillus capsule for vaginal use（1*10^7CFU/capsule）+Metronidazole placebo
- **DRUG:** Low-dose group: Live double combined lactobacillus capsule placebo+Metronidazole
- **DRUG:** Live double combined lactobacillus capsule for vaginal use（1*10^8CFU/capsule）+Metronidazole placebo
- **DRUG:** Medium-dose group: Live double combined lactobacillus capsule placebo+Metronidazole
- **DRUG:** Live double combined lactobacillus capsule for vaginal use（1*10^9CFU/capsule）+Metronidazole placebo
- **DRUG:** High-dose group: Live double combined lactobacillus capsule placebo+Metronidazole

## Key facts

- **NCT ID:** NCT07418996
- **Lead sponsor:** Guangdong Longchuangji Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-18
- **Primary completion:** 2022-07-04
- **Final completion:** 2022-09-30
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07418996

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07418996, "Live Double Combined Lactobacillus Capsule for Vaginal Use（IIa）". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07418996. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*